Literature DB >> 9798916

Generation and regulation of beta-amyloid peptide variants by neurons.

G K Gouras1, H Xu, J N Jovanovic, J D Buxbaum, R Wang, P Greengard, N R Relkin, S Gandy.   

Abstract

Studies of processing of the Alzheimer beta-amyloid precursor protein (betaAPP) have been performed to date mostly in continuous cell lines and indicate the existence of two principal metabolic pathways: the "beta-secretase" pathway, which generates beta-amyloid (A beta(1-40/42); approximately 4 kDa), and the "alpha-secretase" pathway, which generates a smaller fragment, the "p3" peptide (A beta(17-40/42); approximately 3 kDa). To determine whether similar processing events underlie betaAPP metabolism in neurons, media were examined following conditioning by primary neuronal cultures derived from embryonic day 17 rats. Immunoprecipitates of conditioned media derived from [35S]methionine pulse-labeled primary neuronal cultures contained 4- and 3-kDa A beta-related species. Radiosequencing analysis revealed that the 4-kDa band corresponded to conventional A beta beginning at position A beta(Asp1), whereas both radiosequencing and immunoprecipitation-mass spectrometry analyses indicated that the 3-kDa species in these conditioned media began with A beta(Glu11) at the N terminus, rather than A beta(Leu17) as does the conventional p3 peptide. Either activation of protein kinase C or inhibition of protein phosphatase 1/2A increased soluble betaAPP(alpha) release and decreased generation of both the 4-kDa A beta and the 3-kDa N-truncated A beta. Unlike results obtained with continuously cultured cells, protein phosphatase 1/2A inhibitors were more potent at reducing A beta secretion by neurons than were protein kinase C activators. These data indicate that rodent neurons generate abundant A beta variant peptides and emphasize the role of protein phosphatases in modulating neuronal A beta generation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9798916     DOI: 10.1046/j.1471-4159.1998.71051920.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  36 in total

1.  Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling.

Authors:  L Gasparini; G K Gouras; R Wang; R S Gross; M F Beal; P Greengard; H Xu
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

2.  Intraneuronal Abeta42 accumulation in human brain.

Authors:  G K Gouras; J Tsai; J Naslund; B Vincent; M Edgar; F Checler; J P Greenfield; V Haroutunian; J D Buxbaum; H Xu; P Greengard; N R Relkin
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

3.  Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides.

Authors:  G K Gouras; H Xu; R S Gross; J P Greenfield; B Hai; R Wang; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

4.  Critical role of intraneuronal Aβ in Alzheimer's disease: technical challenges in studying intracellular Aβ.

Authors:  Gunnar K Gouras; Katarina Willén; Davide Tampellini
Journal:  Life Sci       Date:  2012-06-19       Impact factor: 5.037

5.  Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers.

Authors:  Sam Gandy; Adam J Simon; John W Steele; Alex L Lublin; James J Lah; Lary C Walker; Allan I Levey; Grant A Krafft; Efrat Levy; Frédéric Checler; Charles Glabe; Warren B Bilker; Ted Abel; James Schmeidler; Michelle E Ehrlich
Journal:  Ann Neurol       Date:  2010-08       Impact factor: 10.422

Review 6.  The beta-secretase, BACE: a prime drug target for Alzheimer's disease.

Authors:  R Vassar
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

7.  Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides.

Authors:  J P Greenfield; J Tsai; G K Gouras; B Hai; G Thinakaran; F Checler; S S Sisodia; P Greengard; H Xu
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

8.  Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology.

Authors:  Reisuke H Takahashi; Teresa A Milner; Feng Li; Ellen E Nam; Mark A Edgar; Haruyasu Yamaguchi; M Flint Beal; Huaxi Xu; Paul Greengard; Gunnar K Gouras
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

9.  The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Authors:  S L Cole; R Vassar
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

10.  Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo.

Authors:  John W Steele; Soong H Kim; John R Cirrito; Deborah K Verges; Jessica L Restivo; David Westaway; Paul Fraser; Peter St George Hyslop; Mary Sano; Ilya Bezprozvanny; Michelle E Ehrlich; David M Holtzman; Sam Gandy
Journal:  Mol Neurodegener       Date:  2009-12-17       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.